• SENSEX
    NIFTY 50
Healthcare

Brokerages on Sun Pharma Q4 results: Most stay bullish but cut target price in Rs 470-540 range

Updated : May 29, 2019 08:45 AM IST

Sun Pharma reported a 53 percent drop in its net profit to Rs 635.9 crore for the quarter ended March 2019.
Citi Research placed the highest target price on Sun Pharma at Rs 540 per share, saying that the underlying numbers and trends indicate improvement QoQ.
Morgan Stanley gave a 'sell' call with a price target of Rs 470 per share.
Brokerages on Sun Pharma Q4 results: Most stay bullish but cut target price in Rs 470-540 range

You May Also Like

Live TV

recommended for you

Advertisement